WuXi AppTec sues Pentagon over Chinese military designation

WuXi AppTec has gone to federal court in Washington, challenging its inclusion on the Pentagon’s list of Chinese military companies and asking a judge to wipe the designation away. The complaint, filed June 11 in the U.S. District Court for the District of Columbia, says the company’s listing is wrong and unsupported by the facts or the legal criteria the Defense Department is supposed to apply.

The case lands at a sensitive moment for U.S.-China economic relations. The Pentagon updated its Section 1260H roster on June 8, and the Federal Register notice followed on June 10, adding 28 entities to a list that now reaches beyond classic defense names into technology, manufacturing and life sciences. Section 1260H comes from the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021, which directs the Defense Department to identify Chinese military companies operating directly or indirectly in the United States.

Washington says the listed firms qualify as Chinese military companies and operate in the United States in some form. In WuXi’s case, the government’s view is more layered: an ACS and C&EN report said the Pentagon described the company as indirectly owned by an institution under China’s State Council and indirectly affiliated with an agency in China’s Ministry of Industry and Information Technology, as well as with the People’s Liberation Army. That is the kind of national-security rationale that can carry far beyond the courtroom, shaping how investors, customers and counterparties judge the company before any judge weighs the evidence.

That is what makes the lawsuit more than a corporate dispute. WuXi AppTec is a major drug developer and contract manufacturing player, and its presence on the list raises immediate questions for U.S. drugmakers and biotech firms that rely on Chinese suppliers for development, manufacturing and related services. A designation of this kind can chill financing, complicate partnerships and trigger procurement headaches even without a formal sanctions regime.

The market reacted immediately. Hong Kong-listed WuXi AppTec shares fell as much as 8% after the Pentagon moved to include the company, a reminder that security designations can hit valuation fast. For Washington, the case is a test of how far it can go in labeling private Chinese firms as national-security risks without publicly proving the link. For WuXi, it is a fight over whether access to global capital and U.S. biotech business can survive a designation that the company says should never have been imposed.